N/A
N=390
A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis
Lumbar Spinal Stenosis
Bottom Line
View on ClinicalTrials.gov: NCT00401518 ↗Enrolled (actual)
390
Serious AEs
44.0%
Results posted
Sep 2020
Primary outcome: Primary: Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score — 1.7; 1.6; 1.7 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Non-randomized ACADIA® Facet Replacement System (Device); Randomized ACADIA® Facet Replacement System (Device); Randomized Instrumented posterolateral fusion (PLF) (Device)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Globus Medical Inc
- Primary completion
- Aug 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score |
1.7; 1.6; 1.7 | — |
| PRIMARY Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Symptom Severity Score |
2.1; 2.0; 2.2 | — |
| PRIMARY Number of Participants Who Maintained or Improved in Neurological Status. |
30; 155; 75 | — |
| SECONDARY Mean Visual Analog Scale (VAS) Right Leg Pain |
19.4; 13.2; 22.5 | — |
| SECONDARY Mean Visual Analog Scale (VAS) Left Leg Pain |
17.5; 12.2; 16.9 | — |
| SECONDARY Mean Visual Analog Scale (VAS) Back Pain |
24.7; 18.8; 23.9 | — |
| SECONDARY Number of Participants With a Change of at Least 15 Points in Pain/Disability Using the Oswestry Disability Index (ODI) Score at 24 Months Compared With the Score at Baseline |
33; 151; 62 | — |
Summary
The purpose of this study is to determine if the ACADIA® Facet Replacement System is effective in the treatment of spinal stenosis. The primary objective of the study is to evaluate the overall success rate of the Anatomic Facet Replacement System in patients with spinal stenosis when compared to a posterior spinal fusion control.
Eligibility Criteria
Inclusion Criteria
- 21-85 years of age and skeletally mature;
- Have undergone 6 months of non-operative treatment prior to surgery;
- Lateral, lateral recess and/or central canal stenosis;
- Disc height measuring ≥ 4 mm at the operative level;
- Persistent leg, thigh and/or buttock symptoms,including pain,numbness, burning or tingling with a minimum leg pain score of 40mm as measured with the Visual Analogue Scale (VAS) Index;
- A score greater than 2 on a scale of 1-5 on the Zurich Claudication Questionnaire (ZCQ) Symptom Severity (SS) Score-Candidate;
- A score greater than or equal to 2 on a scale of 1-4 on the ZCQ Physical Function (PF) Score;
- A candidate for a decompression with full facetectomy at the operative level
- Candidate for a posterior lumbar fusion;
- Physically and mentally willing and able to comply evaluations;
- Lives in the immediate area and has no plans to relocate;
Exclusion Criteria
- Previous surgical procedure at the operative or adjacent level except for one of the following: Micro-discectomy, laminectomy, lamino/foraminotomy, rhizotomy, IDET, and/or interspinous spacer;
- Previous lumbar fusion or disc replacement procedure;
- Osteoporosis;
- greater than Grade I spondylolisthesis or retrolisthesis;
- Spondylolisthesis at levels other than at the operative level;
- Scoliosis of the lumbar spine (defined as more than 11 deg Cobb angle) as indicated by plain X-ray films;
- Primary diagnosis of discogenic back pain due to torn, herniated, inflamed or irritated disc or other pathology where the patient exhibits axial back pain from degenerative disc disease;
- Acute traumatic pars fracture at the operative/adjacent level vertebral body;
- Spinal stenosis at more than three lumbar segments;
- Acute trauma to the lumbar spine within the last 24 months;
- Active infection at the operative level, or a systemic infection;
- Physically / mentally compromised;
- Systemic disease that would affect the patient's welfare or the research study.
- Immunologically suppressed or immunocompromised;
- Insulin-Dependent Diabetes Mellitus (Type I Diabetes);
- Currently undergoing long-term steroid therapy;
- Metabolic bone disease;
- Active malignancy: (except non-melanoma skin cancer), unless treated with no clinical signs or symptoms of the malignancy for at least 5 years;
- Known allergy to cobalt chromium or titanium;
- Used any investigational drug or device within the past 30 days;
- Pending litigation related to back pain or injury;
- Is a prisoner.
Data sourced from ClinicalTrials.gov (NCT00401518). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.